Last week, the Food and Drug Administration (FDA) released a “Drug Safety Communication,” warning that Veozah (fezolinetant), a new medicine to treat hot flashes due to menopause, can cause ...

The FDA says women who are taking Veozah may need more frequent blood testing to check for markers of liver problems. In rare cases, the drug may seriously injure the liver, and patients with ...

FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box Warning By Denise Maher HealthDay Reporter WEDNESDAY, Dec. 18, 2024 (HealthDay News) -- The U.S. Food and Drug Administration (FDA ...

The U.S. Food and Drug Administration (FDA) has issued its most serious warning -- a black-box warning -- for Veozah, a ...

This chemical causes vasomotor symptoms, or hot flashes and night sweats. Veozah blocks the chemical NKB, reducing night sweats and hot flashes. Studies looked at how Veozah affected how ...

The FDA has added a boxed warning to the labeling of Veozah, a medication used to treat hot flashes, highlighting a rare but serious risk of liver injury. The agency added recommendations for ...

Hepatic function should be evaluated prior to initiating treatment with Veozah. The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk ...

The FDA has issued a black-box warning for Veozah, a hot-flash medication, due to rare but serious liver risks Regular liver testing is recommended during Veozah treatment to ensure early ...